LIBRETTO-432: A phase 3 study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive (RET plus ) NSCLC.

被引：0
作者：
Goldman, Jonathan W.
Sands, Jacob
Hallqvist, Andreas
Kim, Hye Ryun
Li, Guoping
Wu, Lin
Su, Weiji
Bayt, Theresa
Yang, Xue-Ning
Hochmair, Maximilian
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA
[2] Dana Farber Canc Inst, Boston, MA USA
[3] Sahlgrens Univ Hosp, Inst Clin Sci, Dept Oncol, Gothenburg, Sweden
[4] Yonsei Univ, Div Med Oncol, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[5] Third Peoples Hosp Chengdu, Chengdu Inst Resp Hlth, Branch Natl Clin Res Ctr Resp Dis, Chengdu, Peoples R China
[6] Hunan Canc Hosp, Thorac Internal Med Oncol Dept, Changsha, Hunan, Peoples R China
[7] Eli Lilly & Co, Indianapolis, IN USA
[8] Eil Lilly & Co, Indianapolis, IN USA
[9] Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangzhou, Peoples R China
[10] Klin Floridsdorf, Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Vienna, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8115
引用
收藏
页数：1
相关论文
共 50 条
[31]   Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer and thyroid cancer, and RET-mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial [J].
Lu, Shun ;
Zheng, Xiangqian ;
Sun, Yuping ;
Huang, Dingzhi ;
Wu, Lin ;
Ji, Qinghai ;
Zhou, Chengzhi ;
Zhou, Jianying ;
Guo, Ye ;
Ge, Minghua ;
Ding, Ding ;
Shao, Jingxin ;
Zhang, Wanli ;
Gao, Ming ;
Cheng, Ying .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[32]   Intracranial Activity of Selpercatinib in Chinese Patients With Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial (JUNR, 10.1200/PO.22.00708, 2023) [J].
Cheng .
JCO PRECISION ONCOLOGY, 2023, 7
[33]   AN UPDATE OF THE PHASE III STUDY OF ADJUVANT VINORELBINE PLUS CISPLATIN (NP) VERSUS NP PLUS ENDOSTAR (NPE) IN PATIENTS WITH COMPLETELY RESECTED STAGE IB-IIIA NON-SMALL CELL LUNG CANCER (NSCLC) [J].
He, Jie ;
Zhang, Xiangru ;
Li, Junling ;
Han, Baohui ;
Liu, Yongyu ;
Wu, Shixiu ;
Kuang, Y. ;
Shen, Yi ;
Chen, Chun ;
Wang, Qun ;
Li, Qiang ;
Ma, Haitao ;
Xu, Shidong ;
Xu, Shaofa ;
Wang, P. ;
Mao, Weimin ;
Pang, Z. ;
Hou, S. ;
Yang, Y. .
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) :S1318-S1319
[34]   Phase II study of induction and adjuvant bevacizumab in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) receiving induction docetaxel and cisplatin [J].
Price, K. ;
Kris, M. G. ;
Rusch, V. ;
Finley, D. J. ;
Azzoli, C. G. ;
Downey, R. J. ;
Bains, M. S. ;
Miller, V. A. ;
Rizk, N. ;
Rizvi, N. A. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[35]   Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial [J].
Subbiah, Vivek ;
Wolf, Jurgen ;
Konda, Bhavana ;
Kang, Hyunseok ;
Spira, Alexander ;
Weiss, Jared ;
Takeda, Masayuki ;
Ohe, Yuichiro ;
Khan, Saad ;
Ohashi, Kadoaki ;
Soldatenkova, Victoria ;
Szymczak, Sylwia ;
Sullivan, Loretta ;
Wright, Jennifer ;
Drilon, Alexander .
LANCET ONCOLOGY, 2022, 23 (10) :1261-1273
[36]   ALINA: a phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB-IIIA anaplastic lymphoma kinase-positive (ALK +) non-small cell cancer (NSCLC) [J].
Rittmeyer, A. ;
Solomon, B. ;
Ahn, J. S. ;
Barlesi, F. ;
Dziadziuszko, R. ;
Nishio, M. ;
Shaw, A. ;
Bordogna, W. ;
Meyenberg, C. ;
Wu, Y. L. .
PNEUMOLOGIE, 2020, 74 :S129-S130
[37]   AcceleRET Lung: A Phase 3 Study of First-Line Pralsetinib in Patients with RET-Fusion plus Advanced/Metastatic NSCLC [J].
Besse, B. ;
Felip, E. ;
Kim, E. S. ;
Clifford, C. ;
Louie-Gao, M. ;
Yagui-Beltran, A. ;
Popat, S. .
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) :S684-S684
[38]   AcceleRET Lung: A Phase 3 Study of First-Line Pralsetinib in Patients with RET-Fusion plus Advanced/Metastatic NSCLC [J].
Besse, B. ;
Felip, E. ;
Kim, E. S. ;
Clifford, C. ;
Louie-Gao, M. ;
Yagui-Beltran, A. ;
Popat, S. .
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) :S44-S45
[39]   Adjuvant Erlotinib (E) Versus Placebo (P) for Completely Resected Stage IB-IIIA EGFR-Positive (IHC/FISH) Non-Small Cell Lung Cancer (NSCLC): RADIANT Results [J].
Altorki, N. K. ;
O'brien, M. E. R. ;
Eberhardt, W. E. E. ;
Richardson, F. C. ;
Wang, J. ;
Foley, M. A. ;
Horan, J. D. ;
Shepherd, F. A. ;
Kelly, K. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 :S2-S3
[40]   Update of a phase III trial of adjuvant vinorelbine plus cisplatin (NP) versus NP plus endostar (NPE) in patients with completely resected stage IB-IIIA non-small cell lung cancer (NSCLC) [J].
Jie, He ;
Han, Baohui ;
Liu, Yongyu ;
Wu, Shi Xiu ;
Kuang, Yukang ;
Shen, Yi ;
Chen, Chun ;
Wang, Qun ;
Li, Qiang ;
Ma Haitao ;
Xu, Shaofa ;
Xu, Shidong ;
Wang, Ping ;
Mao, Weimin ;
Pang, Zuoliang ;
Hou, Shengcai ;
Yang, Yue .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345